Sphera Funds Management’s Sutro Biopharma STRO Stock Holding History

Sphera Funds Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-28,170	Closed	-$4.19M	–	92
2021 Q4	$4.19M	Sell	28,170 -1,313	-4%	-$235K	0.46%	58
2021 Q3	$5.57M	Hold	29,483	–	–	0.47%	64
2021 Q2	$5.48M	Hold	29,483	–	–	0.37%	69
2021 Q1	$6.71M	Buy	29,483 +9,323	+46%	+$2.21M	0.51%	58
2020 Q4	$4.38M	Buy	+20,160	New	+$3.34M	0.39%	74
2019 Q4	–	Sell	-42,259	Closed	-$3.84M	–	96
2019 Q3	$3.84M	Sell	42,259 -2,330	-5%	-$235K	0.59%	52
2019 Q2	$5.07M	Buy	44,589 +800	+2%	+$88.2K	0.69%	40
2019 Q1	$4.99M	Buy	43,789 +3,000	+7%	+$312K	0.46%	51
2018 Q4	$3.68M	Buy	40,789 +13,289	+48%	+$1.6M	0.41%	53
2018 Q3	$4.13M	Buy	+27,500	New	+$4.15M	0.47%	61

Other funds holding STRO

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Sphera Funds Management's STRO Position: Q1 2022 in Review

Sphera Funds Management sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 28,170 shares — an estimated $4.19M sold.

Sphera Funds Management first reported a position in STRO in Q3 2018 and held it in 10 quarters. The position peaked at $6.71M in Q1 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

Sphera Funds Management reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
Sphera Funds Management sold 28,170 Sutro Biopharma shares in Q1 2022, an estimated $4.19M.
Sphera Funds Management first reported a position in Sutro Biopharma in Q3 2018 and held it in 10 quarters.
Sphera Funds Management's Sutro Biopharma position peaked at $6.71M in Q1 2021.
114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on Sphera Funds Management's 13F filing for Q1 2022, filed 16 May 2022.